Copan Diagnostics Receives the US FDA’s 510(k) Clearance for Colibrí to Expand Automated ID/AST Capabilities
Shots:
- The company received the third US FDA clearance for Colibrí, a pre-analytical processor system that is a fully automated platform designed to prepare MALDI-TOF ID targets & create bacterial suspensions for Antibiotic Susceptibility Testing (AST)
- The clearance was granted to Colibri due to its ability to integrate with the Beckman Coulter MicroScan Walkaway Instruments & Pannels for ID/AST as the Colibri system automates the preparation of microbial suspension at a known concentration for the MicroScan System
- The Colibri system with Copan's PhenoMATRIX develops AI-driven solutions for specimen workup in clinical laboratories. Earlier in 2022, Colibri received the US FDA’s 510(k) clearance for use with MALDI-TOF Mass Spectrometry Analyzers and bioMérieux VITEK 2
Ref: PR Newswire | Image: Copan Diagnostics
Related News:- Novartis Reports Positive Results of Iptacopan in P-III (APPEAR-C3G) for the Treatment of C3 glomerulopathy (C3G)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
